New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 4, 2014
07:40 EDTESRX, INSYInsys valuation could be $4 lower on Subsys exclusion, says Wells Fargo
After another research firm stated that Insys' (INSY) Subsys would be placed on Express Scripts' (ESRX) list of excluded drugs, Wells Fargo estimates that such a development could reduce Insys' valuation by about $4. The firm notes that the stock fell $4.16 on July 31 and August 1. It keeps an Outperform rating on the shares.
News For INSY;ESRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 22, 2015
11:05 EDTINSYInsys Therapeutics granted orphan status for ovarian cancer treatment
Subscribe for More Information
January 21, 2015
10:28 EDTESRXLeerink pharmaceuticals analyst holds an analyst/industry conference call
Subscribe for More Information
10:01 EDTESRXOn the Fly: Analyst Initiation Summary
Subscribe for More Information
07:36 EDTESRXExpress Scripts initiated with an Equal Weight at Stephens
Subscribe for More Information
January 20, 2015
06:44 EDTESRXExpress Scripts downgraded to Neutral from Buy at UBS
Subscribe for More Information
January 13, 2015
12:17 EDTESRXExpress Scripts CEO says new cholesterol lowering drugs 'pretty expensive'
12:15 EDTESRXExpress Scripts CEO says Gilead relationship 'important' going forward
Express Scripts (ESRX) CEO George Paz at the J.P. Morgan Healthcare Conference said his company's relationship with Gilead (GILD) is "important" going forward. Paz said his company's goal is not to exclude drugs. He continues to discuss Express Scripts's deal with AbbVie (ABBV) and the company's goal of saving clients money with regards to healthcare costs.
12:10 EDTESRXExpress Scripts CEO says 'never stopped talking to Gilead'
Subscribe for More Information
January 12, 2015
07:02 EDTINSYInsys Therapeutics to initiate five Phase III trials in FY15
Insys Therapeutics announced progress and expected milestones for multiple projects in its pipeline of innovative supportive care and therapy products and candidates. The company intends to submit a New Drug Application to the FDA and to advance five programs into Phase III clinical trials in 2015.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use